In recent years, studies have shown that enhancer RNAs (eRNAs) can be transcribed from enhancers. Increasing evidence has revealed that eRNAs play critical roles in the development of various cancers. Oestrogen-associated eRNAs are closely related to breast cancer. In view of the gender differences in bladder cancer (BCa), we suppose that oestrogen-associated eRNAs are also involved in tumorigenesis of 
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| INTRODUCTION
Bladder cancer is the most common malignant neoplasm of the urinary system, with the occurrence of approximately 429 800 new cases and 165 100 deaths worldwide in 2012. 1 The aetiology of BCa is intricate. Smoking, excessive chemical exposure and chronic inflammation caused by urinary schistosomiasis could all lead to the occurrence of BCa. [1] [2] [3] [4] [5] [6] Global statistics has shown that sex hormones also play an important role in the initiation and invasion of BCa, as the incidence of BCa in males has increased 3.3 times higher than that of females, but the latter tend to be more aggressive and cause twice mortality than males with BCa. 7, 8 However, the molecular mechanisms of oestrogen in BCa remain elusive.
Enhancers are cis-regulatory elements with the ability to increase target gene transcription independent of the distance and direction relative to the promoters. 9 It is generally accepted that enhancers and promoters are physically close together to form enhancerpromoter looping (E:P looping) to enhance the expression of target genes. 10, 11 In recent years, an amazing discovery revealed more complicated roles of enhancers in gene transcriptional activation.
Enhancers could transcribe into enhancer RNAs (eRNAs) uni-or bi-directionally similar to the promoters when respond to various stimulations. 12 18 Gosh et al 19 were the first to show that GREB1 was an oestrogen regulated gene and played an important role in hormone-responsive cancer. GREB1 promoted oestrogenstimulated proliferation of breast cancer, 19 prostate cancer 20 and endometriosis. 21 Oestrogen could induce the transcription of the corresponding enhancers of GREB1, giving rise to GREB1 eRNA (eGREB1) production in MCF-7. 12, 16 In view of the continuous existence of gender differences in BCa, oestrogen seems to be especially important in BCa progression. It is necessary to elucidate whether eGREB1 participated in the action of oestrogen on BCa.
In this study, we examined eGREB1 expression in BCa tissues and investigated the effect of eGREB1 knockdown on the proliferation, migration, invasion and apoptosis of BCa cells T24 and 5637. Moreover, we explored whether eGREB1 knockdown could influence oestrogen-induced biological behaviours of BCa cells. Our work aims to clarify the potential molecular mechanisms of oestrogen-induced BCa and provides new insights for the prevention of BCa.
| MATERIALS AND METHODS

| Patient samples
We collected 38 tumour tissues and matched normal bladder tissues from patients diagnosed with bladder urothelial carcinoma. All samples were snap-frozen in liquid nitrogen immediately after partial or radical cystectomy. We got the written informed consents from all the BCa patients included in this study. The Institutional Review
Board of Shenzhen Second People's Hospital approved the study.
| Cell culture and treatments
Human bladder cancer cell lines (T24, 5637) were purchased from the America Type Culture Collection (ATCC, Manassas, VA, USA).
The T24 cells and 5637 cells were cultured in phenol-free DMEM medium or phenol-free RPMI-1640 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% charcoalstripped foetal bovine serum (Gibco) and 1% antibiotics (100U/mL penicillin and 100 μg/mL streptomycin sulphates). All cells were placed in a humidified atmosphere of 5% CO 2 at 37°C. The cells were treated with 10 nM E2 (Sigma) or DMSO (Sigma) for 1 hour to induce eGREB1 expression. Antisense: 5′-AUUCCGUCAAGCUUGAAUCUCUCUG-3′. 16 T24 and 5637 were cultured in 6-well plates. When grown to 40%-50% confluence, they were transiently transfected with 50 nM si-eGREB1 or si-NC using Lipofectamine 3000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the protocol.
CRISPR-Cas13a vectors targeting eGREB1 (Cas13a-eGREB1) and negative control (Cas13a-NC) were designed and constructed by Syngen Tech Co., Beijing, China. T24 and 5637 were cultured in 6-well plates and were transfected with 2.5ug Cas13a-eGREB1 or Cas13a-NC when they were grown to 80%-90% confluence as before.
| Real-time quantitative PCR (RT-qPCR)
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was converted from total RNA using a Revertra Ace qPCR RT Kit 
| Transwell assay
The cells were treated with Cas13a-eGREB1 or Cas13a-NC for 
| Caspase 3 ELISA assay
Bladder cancer 5637 and T24 cells were transfected with Cas13a vectors in petri plates. Twenty-hour hours after transfection, apoptosis was detected by measuring the activity of caspase 3 using the caspase 3 enzyme-linked immunosorbent assay (ELISA) assay kit (Cusabio, Wuhan, China) according to the manufacturer's instructions. OD values were measured at 450 nm using a microplate reader (Bio-Rad).
| Statistical analysis
All data were presented as mean ± standard deviation (SD). The eGREB1 expression differences between BCa tissues and matched normal tissues were analysed using paired samples t test. The CCK-8 assay was analysed using ANOVA. Other data were analysed by the independent samples t test. All these statistical analyses were performed using SPSS 17. A P value of less than 0.05 was considered to be statistically significant.
| Results
| eGREB1 was up-regulated in BCa tissues and it was related to clinical-pathological features
The relative expression level of eGREB1 in a total of 38 patients | 5921 siRNA ( Figure 1C , P = 0.455 in T24; P = 0.646 in 5637). However, for the cells transfected with CRISPR-Cas13a, the relative expression levels of eGREB1 were reduced to 27.71% and 37.06% in T24 and 5637 cell lines, respectively ( Figure 1D , P < 0.01 in T24 and 5637).
Thus, only CRISPR-Cas13a is suitable for the knockdown study on eGREB1.
| Oestrogen induced the production of eGREB1 in BCa cells
To explore whether oestrogen could induce eGREB1 transcription in BCa cells, we analysed eGREB1 expression after E2 stimulation for 1 h in T24 and 5637. Our results showed the relative expression level of eGREB1 increased by 2.87-fold in T24 (P < 0.001) and 2.74-fold in 5637 (P < 0.01), respectively ( Figure 1E ). We demonstrated that eGREB1 expression was significantly raised in BCa cells when stimulated by oestrogen.
| eGREB1 knockdown inhibited cell proliferation, migration, invasion and promoted apoptosis in BCa cells
Next, we investigated the effect of eGREB1 knockdown on the biological characteristics of BCa cells. After transfection with *P < 0.05 was considered significant; **P < 0.01.
Cas13a-eGREB1 for 24 h, we used CCK8 to compare the cell proliferation rates between the eGREB1 knockdown group and the control group. The results suggested eGREB1 knockdown prominently impaired cell growth in T24 (P < 0.01) and 5637 (P < 0.01) (Figure 2A, B) . Wound healing assay was used to compare the ability of migration between the two groups. In contrast, the knockdown group's migration ratio decreased by 12.07% in T24
(P = 0.001) and 13.61% in 5637 (P < 0.01), respectively ( Experiments were performed in triplicate. Data were shown as mean ± SD (*P < 0.05, **P < 0.01) T24, P < 0.05 in 5637). These results indicated the potential role of eGREB1 in promoting BCa.
| eGREB1 knockdown attenuated the cancer-promoting effect of oestrogen
We revalidated the cancer-promoting effect of oestrogen on BCa.
Oestrogen promoted the cell proliferation ( Figure 3A , B, P < 0.01 in and 5637), migration ( Figure 3C -E, P < 0.001 in T24, P < 0.01 in 5637), invasion ( Figure 4A -C, P < 0.01 in T24 and 5637) and inhibited apoptosis ( Figure 4D , P < 0.05 in T24, P < 0.01 in 5637).
Subsequently, BCa cells were transfected with Cas13a-eGREB1 or Cas13a-NC vectors and treated with oestrogen meanwhile. We compared their biological behaviours using the methods described above. For the group of eGREB1 knockdown with oestrogen treatment, the cell proliferation was obviously decreased ( Figure 3A , B, P < 0.01 in T24 and 5637); the cell migration ratio were reduced by 11.68% in T24 and 18.28% in 5637 ( Figure 3C -E, P < 0.001 in T24 and 5637); the invasive ability of the cells is also prominently weakened ( Figure 4A -C, P < 0.01 in T24 and 5637); ELISA assay showed that the activity of caspase-3 were increased ( Figure 4E , P = 0.001 in T24,
Oestrogen promoted cell proliferation and eGREB1 knockdown reduced the pro-proliferative effects of oestrogen in T24 and 5637. (C-E) Oestrogen facilitated cell migration of T24 and 5637. eGREB1 knockdown impaired cell migration induced by oestrogen. Experiments were performed in triplicate. Data were shown as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001) P < 0.001 in 5637). In conclusion, eGREB1 knockdown can attenuate the effect of oestrogen on BCa.
| DISCUSSION
Increasingly evidences implicate that enhancers are functionally important in key cellular processes including cell development, differentiation and apoptosis. eRNAs are generated by the transcription of active enhancers and involve in the development of various diseases by regulating the expression of multiple genes. [22] [23] [24] [25] [26] GREB1 is shown to be one of the most oestrogen-specific genes and plays an important role in oestrogen-mediated transcriptional activation. The corresponding enhancer of GREB1 could transcribe into eGREB1 when exposed to oestrogen. However, the role of eGREB1 in BCa is unclear. There have been reported that oestrogen is of great importance in the biologic aggressiveness of BCa. 27, 28 Anti-oestrogen therapies could inhibit BCa progression. 29, 30 Whether oestrogen pro- our results show that eGREB1 F I G U R E 4 (A-C) Oestrogen promoted the proliferation and down-regulation of eGREB1 attenuated oestrogen-induced invasion of BCa cells. (D) Oestrogen reduced BCa cell apoptosis. (E) eGREB1 knockdown with oestrogen treatment increased cell invasion compared to the control group. Experiments were performed in triplicate. Data were shown as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001) knockdown by siRNA is barely satisfactory. Instead, targeted knockdown of eGREB1 by CRISPR-Cas13a is extremely meaningful. The Cas13a construct could localize to the nucleus and cleave transcripts precisely and efficiently based on the nuclear localization sequence. 38 In summary, we demonstrated that CRISPR-Cas13a is more applicable to knockdown of eRNAs.
To further verify the function of eGREB1 in BCa, we used CRISPR-Cas13a vectors to reduce eGREB1. Cell proliferation inhibition, decreased motility and increased apoptosis were observed in T24 and 5637 cells. These findings indicated that eGREB1 may play positive roles in the occurrence and progression of BCa. Then, we explored the effects of oestrogen on the biological characteristics of BCa and found that oestrogen could promote cell proliferation, migration and invasion and inhibit cell apoptosis, which was consistent with previous studies. 29, 39 Last but most important is that knockdown of eGREB1 is able to reverse oestrogen-induced biological effects on BCa cells. In this way, we suppose that the cancerpromoting effect of oestrogen may be achieved at least in part through the induction of eGREB1.
In conclusion, our study demonstrated the crucial role of eGREB1 
